News
April 18, 2023
Positive preclinical data presented at AACR 2023
Dallas, Texas April 17, 2023 Etira is pleased to announce that multiple abstracts related to their licensed products showed encouraging preclinical activity in metastatic breast cancer and ovarian cancer. The...
April 17, 2023
Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
April 18, 2023 Dallas, Texas We are excited to congratulate one of our founders, Dr. Ratna Vadlamudi, Professor and Vice Chair for Research, Division of Reproductive Research, Department of Obstetrics...
December 9, 2022
Preclinical data on TNBC presented at SABCS 2022
Dallas, Texas Dec 9, 2022: Etira is pleased to report the abstract related to ERX-41 validating its activity in Triple negative breast cancer was presented at the San Antonio Breast...
October 10, 2022
Oncology Times Highlights ERX-41
etiraRx's lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled "Molecule Targets Vulnerability in Triple-Negative Breast Cancer," Dibash Kumar Das,...
July 1, 2022
Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” in Nature Cancer, from...
June 3, 2022
EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials
DALLAS, June 2, 2022 /PRNewswire/ -- A scientific team, led by the scientific founders of EtiraRx, has identified a small molecule, ERX-41, as a novel oral therapeutic agent that may have utility...